ORMP — Oramed Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $171.80m
- $121.19m
- $2.00m
Brief: Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment
Brief: Oramed Reaches 25% Enrollment In Its Second Of Two Concurrent Phase 3 Oral Insulin Trials
Brief: Premas Biotech Secures Licensing Deal For Commercializing Its Vaccine Technology In India
Oramed rises as JV prepares for clinical trials of oral COVID-19 vaccine
Brief: Oramed - Oravax Gearing Up To Begin Clinical Trials For Oral Covid-19 Vaccine, First In Israel, Then In Additional Clinical Sites Internationally
Brief: Oramed Pharmaceuticals Inc - Files For Mixed Shelf Of Up To $250 Million
Brief: Oramed Pharmaceuticals Inc Says On July 15, Co Entered Into Equity Distribution Agreement With Canaccord Genuity Llc - SEC Filing
Oramed Pharmaceuticals Inc reports results for the quarter ended in February - Earnings Summary
Brief: Oramed Pharmaceuticals To Join Russell 2000® And Russell 3000® Indexes
Brief: Oramed Pharmaceuticals Says Entered Into An Equity Distribution Agreement
Brief: Oramed Pharmaceuticals Says Appointed David Silberman, To Serve As CFO, Treasurer And Secretary, Effective July 5, 2021
Brief: Oramed Pharmaceuticals Inc - Currently Advancing Two Primary Programs: Oral Insulin For Diabetes And An Oral Covid Vaccine
Brief: Oramed Pharmaceuticals - On May 6, CFO, Treasurer And Secretary Of Co Resigned From His Positions With Co Effective As Of July 5
Oramed starts second late-stage study of insulin capsule; shares rise
Brief: Oramed Initiates Second Phase 3 Oral Insulin Study Under FDA's Approved Dual Concurrent Protocol
Brief: Oramed Pharmaceuticals Has Screened First Patient In Its Ora-D-013-2 Study
U.S. STOCKS ON THE MOVE-Connect Biopharma Holdings, FedEx, Visa
U.S. STOCKS ON THE MOVE-Clovis, Tesla, Skillz
Oramed: Rises on JV to develop oral COVID-19 vaccines